Genotype assays and third-line ART in resource-limited settings: a simulation and cost-effectiveness analysis of a planned clinical trial

Division of Infectious Disease, Department of Medicine, Massachusetts General Hospital, and Harvard Medical School, Boston, MA 02114, USA.
AIDS (London, England) (Impact Factor: 6.56). 02/2012; 26(9):1083-93. DOI: 10.1097/QAD.0b013e32835221eb
Source: PubMed

ABSTRACT To project the clinical and economic outcomes of a genotype assay for selection of third-line antiretroviral therapy (ART) in resource-limited settings, as per the planned international A5288 trial (MULTI-OCTAVE).
We used the Cost-effectiveness of Preventing AIDS Complications (CEPAC)-International Model to compare three strategies for patients who have failed second-line ART in South Africa: sustained second-line: no genotype assay, all patients remain on second-line ART; A5288: genotype to determine the resistance profile and assign an appropriate regimen; or population-based third-line: no genotype, all patients switch to a potent third-line regimen. Model inputs are from published data in South Africa. Resistance profiles, ART regimens, and efficacy data were those used for trial planning.
Projected life expectancy for sustained second-line, A5288, and population-based third-line are 61.1, 103.8, and 104.2 months. Compared to sustained second-line ($12 ,460), per person lifetime costs increase for the A5288 ($39, 250) and population-based ($44, 120) strategies. The incremental cost-effectiveness ratio of A5288, compared to sustained second-line, is $7500/year of life saved (YLS), and for population-based third-line, compared to A5288, is $154 ,500/YLS. In the A5288 strategy, very late presentation to care, coupled with lengthy delays to obtain the genotype, dramatically reduces 5-year survival, making the population-based third-line strategy more attractive.
We project that, whereas the public health approach to third-line therapy is unaffordable, genotype assays and third-line ART in resource-limited settings will increase survival and be cost-effective compared to the population-based approach, supporting the value of an efficacy study.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Introduction Antiretroviral therapy (ART) in resource-limited settings has expanded in the last decade, reaching >8 million individuals and reducing AIDS mortality and morbidity. Continued success of ART programs will require understanding the emergence of HIV drug resistance patterns among individuals in whom treatment has failed and managing ART from both an individual and public health perspective. We review data on the emergence of HIV drug resistance among individuals in whom first-line therapy has failed and clinical and resistance outcomes of those receiving second-line therapy in resource-limited settings. Results Resistance surveys among patients initiating first-line nonnucleoside reverse-transcriptase inhibitor (NNRTI)-based therapy suggest that 76%-90% of living patients achieve HIV RNA suppression by 12 months after ART initiation. Among patients with detectable HIV RNA at 12 months, HIV drug resistance, primarily due to M184V and NNRTI mutations, has been identified in 60%-72%, although the antiretroviral activity of proposed second-line regimens has been preserved. Complex mutation patterns, including thymidine-analog mutations, K65R, and multinucleoside mutations, are prevalent among cases of treatment failure identified by clinical or immunologic methods. Approximately 22% of patients receiving second-line therapy do not achieve HIV RNA suppression by 6 months, with poor adherence, rather than HIV drug resistance, driving most failures. Major protease inhibitor resistance at the time of second-line failure ranges from 0% to 50%, but studies are limited. Conclusions Resistance of HIV to first-line therapy is predictable at 12 months when evaluated by means of HIV RNA monitoring and, when detected, largely preserves second-line therapy options. Optimizing adherence, performing resistance surveillance, and improving treatment monitoring are critical for long-term prevention of drug resistance.
    The Journal of Infectious Diseases 06/2013; 207 Suppl 2:S49-56. DOI:10.1093/infdis/jit107 · 5.85 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: In sub-Saharan Africa, HIV-infected adults who fail 2-line antiretroviral therapy (ART) often do not have access to 3-line ART. We examined the clinical impact and cost-effectiveness of making 3-line ART available in Côte d'Ivoire. We used a simulation model to compare four strategies following 2-line ART failure: continue 2-line ART [C-ART2]; continue 2-line ART with an adherence reinforcement intervention [AR-ART2]; immediate switch to 3-line ART [IS-ART3]; and continue 2-line ART with adherence reinforcement, switching patients with persistent failure to 3-line ART [AR-ART3]. Third-line ART consisted of a boosted-darunavir plus raltegravir-based regimen. Primary outcomes were 10-year survival and lifetime incremental cost effectiveness ratios (ICERs), in $/year of life saved (YLS). ICERs below $3,585 (3 times the country per capita GDP) were considered cost-effective. Ten-year survival was 6.0% with C-ART2, 17.0% with AR-ART2, 35.4% with IS-ART3, and 37.2% with AR-ART3. AR-ART2 was cost-effective ($1,100/YLS). AR-ART3 had an ICER of $3,600/YLS and became cost-effective if the cost of 3-line ART decreased by <1%. IS-ART3 was less effective and more costly than AR-ART3. Results were robust to wide variations in the efficacy of 3-line ART and of the adherence reinforcement, as well as in the cost 2-line ART. Access to 3-line ART combined with an intense adherence reinforcement phase, used as a tool to distinguish between patients who can still benefit from their current 2-line regimen and those who truly need 3-line ART would provide substantial survival benefits. With minor decreases in drug costs, this strategy would be cost-effective.
    JAIDS Journal of Acquired Immune Deficiency Syndromes 04/2014; DOI:10.1097/QAI.0000000000000166 · 4.39 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Tremendous progress has been made with the scale-up of antiretroviral therapy in Africa, with an estimated seven million people now receiving antiretroviral therapy in the region. The long-term success of antiretroviral therapy programs depends on appropriate strategies to deal with potential threats, one of which is the emergence and spread of antiretroviral drug resistance. Whilst public health surveillance forms the mainstay of the World Health Organization approach to antiretroviral drug resistance, there is likely to be increasing demand for access to drug resistance testing as programs mature and as HIV clinical management becomes more complex. African-owned research initiatives have helped to develop affordable resistance testing appropriate for use in the region, and have developed delivery models for resistance testing at different levels of the public health system. Some upper-middle-income countries such as Botswana and South Africa have introduced drug resistance testing for selected patient groups to guide clinical management. The scale-up of resistance testing will require substantial expansion of clinical and laboratory capacity in the region, but the expertise and resources exist in Africa to support this. The long-term population health impact and cost-effectiveness of resistance testing in the region will also require further investigation.
    AIDS reviews 12/2013; 15(4):221-9. · 4.02 Impact Factor

Full-text (2 Sources)

Available from
May 28, 2014